Drug Approval | November 19, 2022
Eugia Pharma receives USFDA approval for Amphotericin B Liposome for Injection
The product is expected to be launched by Q4 FY23.
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 114.77 crores during the period ended September 30, 2022.
Cyclophosphamide Capsules, 25 mg and 50 mg, have an estimated market size of US$ 8 million for twelve months ending Sep 2022 according to IQVIA.
The company hopes to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Subscribe To Our Newsletter & Stay Updated
